ICICI Venture Funds Management has completed a comprehensive restructuring of its subsidiary RFCL, a company that focuses on in vitro diagnostics, animal healthcare, laboratory solutions and custom synthesis. RFCL operates four strategic business units: Diagnova, Vetnex, Rankem and Neosynth.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.